Findings

What do systematic reviews say?

897 questions · 966 findings · 73 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 269 · 27.8%GRADE not reported 101 · 10.5%Very low 284 · 29.4%Low 180 · 18.6%Moderate 107 · 11.1%High 25 · 2.6%

Hypnotics vs inactive control

Quality of lifeÂ · adults with primary central sleep apnoea

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypnotics vs inactive control

AHI · adults with primary central sleep apnoea

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 5 participants
GRADE not reported

Hypnotics vs inactive control

All‐cause mortality · adults with primary central sleep apnoea

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Carbonic anhydrase inhibitors vs inactive control

Serious adverse events · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Carbonic anhydrase inhibitors vs inactive control

Quality of sleep · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Carbonic anhydrase inhibitors vs inactive control

Quality of life · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Carbonic anhydrase inhibitors vs inactive control

AHI · adults with central sleep apnoea associated with heart failure

2 findings from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low
Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Carbonic anhydrase inhibitors vs inactive control

All‐cause mortality · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anxiolytics vs inactive control

cAHI · adults with central sleep apnoea associated with heart failure

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
GRADE not reported

Antihypertensive drug therapy vs placebo

Number of cases of dementia Range of · participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia

It is very uncertain whether antihypertensive therapy changes number of cases of dementia Range of compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of… 2021 · Cochrane Headline outcomes only
OR 0.89 [0.72, 1.07]
4 studies · 15427 participants
Very low

Antihypertensive drug therapy vs placebo

Change in MMSE · participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia

1 finding from 1 review

Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of… 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 9435 participants
Very low

Antihypertensive drug therapy vs placebo

Systolic blood pressure (mmHg), change from baseline · participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia

1 finding from 1 review

Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of… 2021 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 17793 participants
Low

Antihypertensive drug therapy vs placebo

Diastolic blood pressure (mmHg), change from baseline · participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia

1 finding from 1 review

Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of… 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 15209 participants
Low

Antihypertensive drug therapy vs placebo

Adverse effects Range of · participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia

1 finding from 1 review

Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of… 2021 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 16830 participants
Very low

Antihypertensive drug therapy vs placebo

Quality of life measured via Sickness Impact Profile, PGWB Positive well‐being, and EuroQoL Current Health Range of · participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia

1 finding from 1 review

Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of… 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 15795 participants
Very low

Antidepressants vs placebo

Clinical response of depression · adults with psychotic depression

It is very uncertain whether antidepressant changes clinical response of depression compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
RR 8.4 [0.5, 142.27]
1 study · 27 participants
Very low

Antipsychotics vs placebo

Change in depression severity from baseline · adults with psychotic depression

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antipsychotics vs placebo

Quality of life · adults with psychotic depression

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antipsychotics vs placebo

Acceptability ‐ dropouts due to adverse effects · adults with psychotic depression

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antidepressants vs antidepressants

Clinical response · adults with psychotic depression

1 finding from 1 review

Pharmacological treatment for psychotic depression 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low